The influence of erythropoietin on cytokines in haemodialysis patient

Nephrology

Volumn 3, Issue 5, 1997, Pages 323-327

  Rutkowski, Bolesław ^a   Szołkiewicz, Marek ^a   Manitius, Jacek ^a   Myśliwska, Jolanta ^a   Bryl, Ewa ^a   Myśliwski, Andrzej ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Cytokines; Erythropoietin; Haemodialysis

Indexed keywords

CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 6; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; FEMALE; GLOMERULONEPHRITIS; HEMODIALYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; KIDNEY POLYCYSTIC DISEASE; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030771827     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.1997.tb00250.x     Document Type: Article

References (28)

1. Revillard JP. Immunological alterations in chronic renal insufficiency. Adv. Nephrol. 1979; 8: 365-82.
2. Beaurain B, Naret C, Marcon L et al. In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients. Kidney Int. 1989; 36: 636-44.
3. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor. Kidney Int. 1990; 37: 116-25.
4. Herbelin A, Urena P, Zingraff J, Descamps-Latscha B. Influence of first long-term dialysis on uremia-associated increased basal production of Interleukin-1 and tumor necrosis factor α by circulating monocytes. Nephrol. Dial. Transplant. 1991; 6: 349-57.
5. 2 by macrophages in uremia. Nephrol. Dial. Transplant. 1991; 6: 966-70.
6. Charpentier B, Lang PH, Martin B, Noury J, Metheeu D, Fires D. Depressed polymorphonuclear leukocyte functions associated with normal cytotoxic function of T and natural killer cells during chronic hemodialysis. Clin. Nephrol. 1983; 19: 228-94.
7. Andrew OT, Schoenfeld PY, Hopewell PC, Hunphreys MH. Tuberculosis in patients with end-stage renal disease. Am. J. Med. 1980; 68: 59-65.
8. Lindner A, Farewell VT, Sherrard DJ. High incidence of neoplasia in uremic patients receiving long-term dialysis. Nephron 1981; 27: 292-6.
9. Sethi D, Brown EA, Gower PE. CAPD, protective against developing dialysis-associated amyoloid? Nephron 1988; 50: 85-6.
10. Raska K, Raskova J, Shea SM, Frankel RM, Wood RH. T cell subsets and cellular immunity in end-stage renal disease. Am. J. Med. 1983; 75: 734-40.
11. Chatenoud L, Dugas B, Beaurain G et al. Presence of preactivated T cells in hemodialyzed patients: Their possible role in altered immunity. Proc. Natl. Acad. Sci. USA 1986; 83: 7457-61.
12. Pertosa G, Marfella C, Tarantino EA et al. Involvement of peripheral blood monocytes in hemodialysis: In vivo induction of tumor necrosis factor alpha, Interleukin-6 and β2-microglobulin. Nephrol. Dial. Transplant. 1991; 6 (Suppl. 2) 18-23.
13. Cavaillon JM, Poignet JL, Fitting C, Delons S. Serum Interleukin-6 in long-term hemodialysis patients. Nephron 1991; 60: 307-13.
14. Pa̧czek L, Schaefer RM, Heidland A. Improved function of B lymphocytes in dialysis patients treated by recombinant human erythropoietin. In: Schaefer RM, Heidland A, Horl WH (eds). Erythropoietin in the 90s. Contrib. Nephrol. Basel, Karger 1990; 87: 36-41.
15. Imiela J, Korczak-Kowalska G, Małecki R, Nowaczyk M, Stȩpień-Sopniewska B, Górski A. Immunomodulatory action of human recombinant erythropoietin in man. Immunol. Let. 1993; 35: 271-6.
16. Grimm PC, Sinai-Trieman L, Sekiya NM et al. Effect of recombinant human erythropoietin in HLA sensitization and cell mediated immunity. Kidney Int. 1990; 38: 12-18.
17. Buemi M, Allegra A, Alosi C, Fristina N. Influence of therapy with recombinant erythropoietin on serum levels of neopterin in hemodialyzed subjects. Am. J. Nephrol. 1991; 11: 281-3.
18. Kang XX, Hirano T, Oka K et al. Recovery of decreased ability of peripheral-blood mononuclear cells from chronic renal failure to produce interleukin-1 and β after renal transplantation. Nephron 1991; 58: 450-5.
19. Sennesael JJ, Van der Niepen P, Verbeelen DL. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int. 1991; 40: 121-8.
20. Barany P, Fehrman I, Godoy C. Long-term effects on lymphocytotoxic antibodies and immune reactivity in hemodialysis patients treated with recombinant human erythropoietin. Clin. Nephrol. 1992; 37: 90-6.
21. Myśliwska J, Bryl E, Szołkiewicz M, Manitius J, Myśliwski A, Rutkowski B. Low doses recombinant erythropoietin raise serum Interleukin-2 levels in hemodialysis patients. J. Nephrol. 1996; 9: 30-34.
22. Boswell RN, Yard BA, Schrama E, van Es LA, Daha MR, van der Woude FJ. Interleukin-6 production by human proximal tubular epithelial cells in vitro: Analysis of the effects of Interleukin-1α and other cytokines. Nephrol. Dial. Transplant. 1994; 9: 599-606.
23. Pa̧czek L, Schaefer RM, Heidland A. Dialysis membranes decrease immunoglobulin and interleukin-6 production by peripheral blood mononuclear cells in vitro. Nephrol. Dial. Transplant. 1991; (Suppl. 3): 41-4.
24. Spina CA, Fahey JH, Durkos-Smith D, Dorey F, Sarna G. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy. J. Biol. Response Mod. 1983; 3: 458.
25. Talmadge JE, Herberman RB, Chirigos MA et al. Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2. J. Immunol. 1985; 135: 2483-91.
26. Fung MR, Greene WC. The human interleukin-2 receptor: insight into subunit structure and growth signal transduction. Sem. Immunol. 1990; 2: 119-28.
27. Donati D, Degiannis D, Combates N, Raskova J, Raska K. Evidence of mononuclear cell activation by hemodialysis. ASAIO Transactions 1991; 37: M386-7.
28. Birmingham DJ, Shen XP, Hartman JA, Dillon JJ, Hebert LA. Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. Kidney Int. 1996; 50: 543-9.